Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Stock Information for Biomerica Inc.

Loading

Please wait while we load your information from QuoteMedia.